Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence
- PMID: 20705881
- PMCID: PMC2920776
Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence
Erratum in
- Can Fam Physician. 2010 Nov;56(11):1112
Abstract
Question: I have a patient who has just found out she is pregnant, and she is currently taking paroxetine for severe anxiety and depression. Owing to conflicting results from different studies, as well as my patient hearing about the lawsuit against GlaxoSmithKline, I did try her on other antidepressants; however, only paroxetine was effective, so she restarted it. Now she is pregnant and euthymic, but she is extremely worried about taking the drug. How do I explain the confusing information to her?
Answer: There has recently been an increase in the publication of studies reporting pregnancy outcomes associated with use of antidepressants; many focus on paroxetine, often with conflicting results. However, despite these studies and the precedent-setting lawsuit in which GlaxoSmithKline was ordered to pay $2.5 million to the family of a child with a heart defect whose mother took paroxetine in the first trimester of pregnancy, the evidence that paroxetine increases the rate of cardiac malformations above the population baseline risk of 1 out of 100 pregnancies just does not exist.
QUESTION En 1985, je vous ai demandé conseil pour la première fois à propos d’une de mes patientes qui, ne sachant pas qu’elle était enceinte, avait pris de la tétracycline. J’étais très préoccupé, tout comme ma patiente, qui était prête à mettre un terme à sa grossesse par crainte d’avoir causé des problèmes à son bébé. Directement grâce à vos conseils, le « fœtus » est maintenant l’heureuse mère de 25 ans d’un fils en bonne santé. Votre réponse à ma question se lisait comme suit : Cette femme a été exposée à la tétracycline bien avant la formation des bourgeons dentaires; par conséquent, il n’y a pas de risque fœtal apparent. Selon vous, quels sont certains des plus importants renseignements que vous ayez fournis aux médecins de famille en pratique active au cours des 25 dernières années?
RÉPONSE Malheureusement, trop de décisions dans la prise en charge des femmes enceintes se fondent sur de l’information erronée ou une mauvaise compréhension des risques tératogènes. Il est essentiel de prendre les décisions thérapeutiques concernant les expositions durant la grossesse en faisant un juste équilibre entre les risques de ne pas traiter la maladie maternelle et les renseignements fondés sur les données probantes existants sur la sécurité fœtale.
Similar articles
-
Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence?Birth Defects Res A Clin Mol Teratol. 2010 Mar;88(3):171-4. doi: 10.1002/bdra.20643. Birth Defects Res A Clin Mol Teratol. 2010. PMID: 19950383 No abstract available.
-
First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.Birth Defects Res B Dev Reprod Toxicol. 2007 Feb;80(1):18-27. doi: 10.1002/bdrb.20099. Birth Defects Res B Dev Reprod Toxicol. 2007. PMID: 17187388
-
Paroxetine exposure during pregnancy and cardiac malformations.Birth Defects Res A Clin Mol Teratol. 2010 Mar;88(3):175-7. doi: 10.1002/bdra.20655. Birth Defects Res A Clin Mol Teratol. 2010. PMID: 20175190 No abstract available.
-
Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine.J Clin Psychiatry. 2009 Mar;70(3):414-22. doi: 10.4088/jcp.08r04468. Epub 2009 Feb 24. J Clin Psychiatry. 2009. PMID: 19254517 Review.
-
Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors.Clin Ther. 2007 May;29(5):918-926. doi: 10.1016/j.clinthera.2007.05.003. Clin Ther. 2007. PMID: 17697910 Review.
References
-
- Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005;14(12):823–7. - PubMed
-
- Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194(4):961–6. - PubMed
-
- Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106(6):1289–96. - PubMed
-
- GlaxoSmithKline . Use of paroxetine in first trimester of pregnancy may have a small increased risk of birth defects, compared to other antidepressants. Mississauga, ON: GlaxoSmithKline; 2005. Oct, 2005. Available from: www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/paxil_3_pa-ap-.... Accessed 2010 Jun 8.
-
- Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(10):1075–85. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical